Pfizer Inc. (PFE - Free Report) announced positive results from the phase III study, S-TRAC, (Sunitinib Trial in Adjuvant Renal Cancer) on Sutent.
The randomized, double-blind trial evaluated Sutent in comparison to placebo in the adjuvant setting in patients who are at high risk of renal cell carcinoma (RCC). Results showed that the trial met the primary endpoint of improving disease-free survival as determined by a blinded independent central review in RCC patients with a high risk of recurrence after surgery. Adjuvant therapy is expected to lower the risk of recurrence in patients suffering from early-stage cancer.
Pfizer expects to report full efficacy and safety data from the trial at the ESMO 2016 Congress in Oct 2016.
We note that Sutent is approved for advanced RCC, imatinib-resistant or -intolerant gastrointestinal stromal tumors and advanced pancreatic neuroendocrine tumors. As per the information provided by the company, RCC is the most common type of kidney cancer, accounting for around 90% of all kidney cancers. The product’s sales increased 22% operationally (excluding currency impact) year over year in the first quarter of 2016, primarily driven by price increases in the U.S., as well as strong demand in most markets.
The RCC market is already pretty crowded. Note that the FDA had approved Exelixis, Inc.’s (EXEL - Free Report) Cabometyx in Apr 2016 for the treatment of advanced RCC in patients who received prior anti-angiogenic therapy. In Nov 2015, the FDA approved Opdivo for the same indication.
Pfizer currently carries a Zacks Rank #2 (Buy). Other favorably placed stocks in the healthcare sector include Abbott Laboratories (ABT - Free Report) and Novartis AG (NVS - Free Report) . Both stocks carry the same rank as Pfizer.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Pfizer Inc. (PFE - Free Report) announced positive results from the phase III study, S-TRAC, (Sunitinib Trial in Adjuvant Renal Cancer) on Sutent.
The randomized, double-blind trial evaluated Sutent in comparison to placebo in the adjuvant setting in patients who are at high risk of renal cell carcinoma (RCC). Results showed that the trial met the primary endpoint of improving disease-free survival as determined by a blinded independent central review in RCC patients with a high risk of recurrence after surgery. Adjuvant therapy is expected to lower the risk of recurrence in patients suffering from early-stage cancer.
Pfizer expects to report full efficacy and safety data from the trial at the ESMO 2016 Congress in Oct 2016.
We note that Sutent is approved for advanced RCC, imatinib-resistant or -intolerant gastrointestinal stromal tumors and advanced pancreatic neuroendocrine tumors. As per the information provided by the company, RCC is the most common type of kidney cancer, accounting for around 90% of all kidney cancers. The product’s sales increased 22% operationally (excluding currency impact) year over year in the first quarter of 2016, primarily driven by price increases in the U.S., as well as strong demand in most markets.
The RCC market is already pretty crowded. Note that the FDA had approved Exelixis, Inc.’s (EXEL - Free Report) Cabometyx in Apr 2016 for the treatment of advanced RCC in patients who received prior anti-angiogenic therapy. In Nov 2015, the FDA approved Opdivo for the same indication.
Pfizer currently carries a Zacks Rank #2 (Buy). Other favorably placed stocks in the healthcare sector include Abbott Laboratories (ABT - Free Report) and Novartis AG (NVS - Free Report) . Both stocks carry the same rank as Pfizer.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on ABT - FREE
Get the latest research report on NVS - FREE
Get the latest research report on PFE - FREE
Get the latest research report on EXEL - FREE